

Graeme I Murray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9087169/publications.pdf>

Version: 2024-02-01

126
papers

7,925
citations

44069

48
h-index

51608

86
g-index

127
all docs

127
docs citations

127
times ranked

10529
citing authors

#	ARTICLE	IF	CITATIONS
1	Matrix metalloproteinases in tumour invasion and metastasis. <i>Journal of Pathology</i> , 1999, 189, 300-308.	4.5	565
2	Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. <i>Nature Medicine</i> , 1996, 2, 461-462.	30.7	404
3	REGULATION, FUNCTION, AND TISSUE-SPECIFIC EXPRESSION OF CYTOCHROME P450 CYP1B1. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 297-316.	9.4	296
4	Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. <i>Journal of Pathology</i> , 1998, 185, 256-261.	4.5	244
5	Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. <i>Nature Medicine</i> , 1996, 2, 461-462.	30.7	240
6	Current and emerging concepts in tumour metastasis. <i>Journal of Pathology</i> , 2010, 222, 1-15.	4.5	232
7	Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. <i>Journal of Pathology</i> , 2015, 237, 273-281.	4.5	201
8	Proteomics: a new approach to the study of disease. <i>Journal of Pathology</i> , 2000, 192, 280-288.	4.5	197
9	Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. <i>Journal of Pathology</i> , 2005, 205, 74-81.	4.5	184
10	The Structure, Regulation, and Function of Human Matrix Metalloproteinase-13. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2002, 37, 149-166.	5.2	177
11	Cytochrome P450 enzymes: novel options for cancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 363-71.	4.1	154
12	Cytochrome P450 CYP1B1 protein expression. <i>Biochemical Pharmacology</i> , 2001, 62, 207-212.	4.4	153
13	Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis. <i>Clinical Cancer Research</i> , 2005, 11, 3758-3765.	7.0	152
14	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. <i>Cancer Cell</i> , 2014, 26, 273-287.	16.8	152
15	Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Phenotype Identifies Poor Prognosis Colorectal Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 8229-8234.	7.0	151
16	The Inflammatory Microenvironment in Colorectal Neoplasia. <i>PLoS ONE</i> , 2011, 6, e15366.	2.5	151
17	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. <i>Gut</i> , 2021, 70, 544-554.	12.1	148
18	Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers. <i>Clinical Cancer Research</i> , 2005, 11, 7369-7375.	7.0	145

#	ARTICLE	IF	CITATIONS
19	New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. <i>Journal of Pathology</i> , 2003, 201, 528-534.	4.5	142
20	The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1765, 85-100.	7.4	134
21	Profiling the expression of cytochrome P450 in breast cancer. <i>Histopathology</i> , 2010, 57, 202-211.	2.9	128
22	Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. <i>Journal of Pathology</i> , 2019, 247, 629-640.	4.5	127
23	Tumour Cytochrome P450 and Drug Activation. <i>Current Pharmaceutical Design</i> , 2002, 8, 1335-1347.	1.9	121
24	Lysyl Oxidase Plays a Critical Role in Endothelial Cell Stimulation to Drive Tumor Angiogenesis. <i>Cancer Research</i> , 2013, 73, 583-594.	0.9	114
25	Cyclin D1 protein expression and gene polymorphism in colorectal cancer. <i>International Journal of Cancer</i> , 2000, 88, 77-81.	5.1	108
26	Expression of cytochrome P450 CYP1B1 in breast cancer. <i>FEBS Letters</i> , 1995, 374, 270-272.	2.8	107
27	A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. , 1997, 183, 237-241.		106
28	Profiling markers of prognosis in colorectal cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1184-1191.	7.0	104
29	Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1. <i>Journal of Histochemistry and Cytochemistry</i> , 1999, 47, 1457-1464.	2.5	103
30	The role of cytochrome P450 in tumour development and progression and its potential in therapy. <i>Journal of Pathology</i> , 2000, 192, 419-426.	4.5	103
31	Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2279-2287.	1.6	100
32	Spot the differences: proteomics in cancer research. <i>Lancet Oncology</i> , The, 2001, 2, 270-277.	10.7	91
33	An overview of laser microdissection technologies. <i>Acta Histochemica</i> , 2007, 109, 171-176.	1.8	82
34	Expression of xenobiotic metabolizing enzymes in breast cancer. <i>Journal of Pathology</i> , 1993, 169, 347-353.	4.5	80
35	The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis. <i>PLoS ONE</i> , 2011, 6, e27718.	2.5	78
36	Cytochrome P450 1B1: a novel anticancer therapeutic target. <i>Future Oncology</i> , 2005, 1, 259-263.	2.4	77

#	ARTICLE	IF	CITATIONS
37	Analysis of key cell cycle checkpoint proteins in colorectal tumours. <i>Journal of Pathology</i> , 2002, 196, 386-393.	4.5	75
38	TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. <i>Cancer Cell</i> , 2017, 31, 621-634.e6.	16.8	73
39	The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. <i>Journal of Pathology</i> , 1995, 177, 147-152.	4.5	70
40	Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 500-509.	0.8	70
41	Eniluracil Treatment Completely Inactivates Dihydropyrimidine Dehydrogenase in Colorectal Tumors. <i>Journal of Clinical Oncology</i> , 1999, 17, 2439-2439.	1.6	60
42	The expression of cytochrome P-450, epoxide hydrolase, and glutathione s-transferase in hepatocellular carcinoma. <i>Cancer</i> , 1993, 71, 36-43.	4.1	58
43	Colorectal Tumors Require NIAK1 for Protection from Oxidative Stress. <i>Cancer Discovery</i> , 2018, 8, 632-647.	9.4	57
44	Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. <i>Scientific Reports</i> , 2018, 8, 12096.	3.3	55
45	Biomarkers of colorectal cancer: Recent advances and future challenges. <i>Proteomics - Clinical Applications</i> , 2015, 9, 64-71.	1.6	52
46	The candidate oncogene ZNF217 is frequently amplified in colon cancer. <i>Journal of Pathology</i> , 2004, 204, 282-288.	4.5	51
47	The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. <i>Human Pathology</i> , 2011, 42, 393-402.	2.0	50
48	Human matrix metalloproteinase-9 : activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. <i>FEBS Journal</i> , 1998, 258, 37-43.	0.2	49
49	Current concepts in tumour-derived organoids. <i>British Journal of Cancer</i> , 2020, 123, 1209-1218.	6.4	49
50	Cytochrome P450IA expression in adult and fetal human liver. <i>Carcinogenesis</i> , 1992, 13, 165-169.	2.8	48
51	Matrix metalloproteinases: a multifunctional group of molecules. <i>Journal of Pathology</i> , 2001, 195, 135-137.	4.5	48
52	Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. <i>Cancer Letters</i> , 1999, 139, 199-205.	7.2	45
53	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. <i>British Journal of Cancer</i> , 2020, 123, 1280-1288.	6.4	45
54	Extending colonic mucosal microbiome analysis assessment of colonic lavage as a proxy for endoscopic colonic biopsies. <i>Microbiome</i> , 2016, 4, 61.	11.1	43

#	ARTICLE	IF	CITATIONS
55	The Expression and Prognostic Significance of Retinoic Acid Metabolising Enzymes in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e90776.	2.5	42
56	The Hippo effector <i>TAZ</i> (<i>WWTR1</i>) transforms myoblasts and <i>TAZ</i> abundance is associated with reduced survival in embryonal rhabdomyosarcoma. <i>Journal of Pathology</i> , 2016, 240, 3-14.	4.5	40
57	MICL controls inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1386-1391.	0.9	40
58	Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. <i>Biochemical Pharmacology</i> , 2003, 65, 1663-1674.	4.4	39
59	The use of formalin fixed wax embedded tissue for proteomic analysis: Table 1. <i>Journal of Clinical Pathology</i> , 2011, 64, 297-302.	2.0	39
60	Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia. <i>Cancer Research</i> , 2018, 78, 75-87.	0.9	39
61	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phosphate lyase determines chemotherapy resistance in gastroesophageal cancer. <i>BMC Cancer</i> , 2015, 15, 762.	2.6	38
62	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. <i>British Journal of Cancer</i> , 2017, 117, 203-209.	6.4	38
63	The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. <i>Histopathology</i> , 2009, 54, 820-828.	2.9	36
64	Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma. <i>PLoS ONE</i> , 2015, 10, e0134219.	2.5	34
65	Cellular apoptosis susceptibility (chromosome segregation like <i>CSE1L</i>) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. <i>Journal of Pathology</i> , 2012, 228, 471-481.	4.5	33
66	A Comprehensive Study of Extramural Venous Invasion in Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0144987.	2.5	33
67	Cytochrome P450 CYP3A5 in the human anterior pituitary gland. <i>FEBS Letters</i> , 1995, 364, 79-82.	2.8	32
68	Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer. <i>Oncotarget</i> , 2016, 7, 46509-46527.	1.8	31
69	The Hippo signal transduction pathway in soft tissue sarcomas. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 121-129.	7.4	28
70	Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. <i>Gut</i> , 2014, 63, 480-493.	12.1	26
71	Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. <i>International Journal of Cancer</i> , 2001, 94, 297-301.	5.1	23
72	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. <i>Modern Pathology</i> , 2017, 30, 1287-1298.	5.5	23

#	ARTICLE	IF	CITATIONS
73	Î2-Glucan exacerbates allergic airway responses to house dust mite allergen. <i>Respiratory Research</i> , 2016, 17, 35.	3.6	21
74	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. <i>BMC Cancer</i> , 2020, 20, 500.	2.6	20
75	Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. <i>Journal of Pathology</i> , 1993, 171, 49-52.	4.5	19
76	Integrative analysis of the colorectal cancer proteome: potential clinical impact. <i>Expert Review of Proteomics</i> , 2016, 13, 917-927.	3.0	19
77	The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance. <i>British Journal of Cancer</i> , 2017, 116, 1612-1620.	6.4	19
78	The proteomics of formalin-fixed wax-embedded tissue. <i>Clinical Biochemistry</i> , 2013, 46, 546-551.	1.9	18
79	Proteomics for early detection of colorectal cancer: recent updates. <i>Expert Review of Proteomics</i> , 2018, 15, 55-63.	3.0	18
80	Progress in the identification of plasma biomarkers of colorectal cancer. <i>Proteomics</i> , 2013, 13, 2227-2228.	2.2	17
81	The role of gene regulatory networks in promoting cancer progression and metastasis. <i>Future Oncology</i> , 2014, 10, 735-748.	2.4	17
82	The expression and prognostic significance of bclâ€2â€associated transcription factor 1 in rectal cancer following neoadjuvant therapy. <i>Histopathology</i> , 2016, 68, 556-566.	2.9	17
83	In situ PCR. <i>Journal of Pathology</i> , 1993, 169, 187-188.	4.5	16
84	27 Cytochrome P450 in normal human brain and brain tumours. <i>Biochemical Society Transactions</i> , 1997, 25, S577-S577.	3.4	16
85	Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 372-386.	3.0	16
86	The expression of brown fatâ€associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. <i>International Journal of Cancer</i> , 2019, 145, 1138-1147.	5.1	16
87	CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. <i>International Journal of Experimental Pathology</i> , 2015, 96, 81-86.	1.3	15
88	A Novel Method for Optimum Biopsy Specimen Preservation for Histochemical and Immunohistochemical Analysis. <i>American Journal of Clinical Pathology</i> , 1991, 95, 131-136.	0.7	14
89	Novel biomarkers for risk stratification of Barrettâ€™s oesophagus associated neoplastic progressionâ€epithelial HMGB1 expression and stromal lymphocytic phenotype. <i>British Journal of Cancer</i> , 2020, 122, 545-554.	6.4	14
90	Increased Lymph Node Yield in Colorectal Cancer Is Not Necessarily Associated with a Greater Number of Lymph Node Positive Cancers. <i>PLoS ONE</i> , 2014, 9, e104991.	2.5	11

#	ARTICLE	IF	CITATIONS
91	Progress in the development of protein biomarkers of oesophageal and gastric cancers. <i>Proteomics - Clinical Applications</i> , 2016, 10, 532-545.	1.6	11
92	Is wax on the wane?. <i>Journal of Pathology</i> , 1988, 156, 187-188.	4.5	10
93	Differential expression of CYP1A1 and CYP1B1 in human breast cancer. <i>Biochemical Society Transactions</i> , 1996, 24, 327S-327S.	3.4	10
94	An Introduction to Laser-Based Tissue Microdissection Techniques. , 2005, 293, 3-7.		10
95	The distribution of different forms of cytochrome P-450 in human liver. <i>Biochemical Society Transactions</i> , 1990, 18, 1202-1202.	3.4	9
96	Biomarkers for Colorectal Cancer: Identification Through Proteomics. <i>Current Proteomics</i> , 2010, 7, 212-221.	0.3	9
97	Immunohistochemical localization of glutathione s-transferases in sarcomas. <i>Journal of Pathology</i> , 1994, 174, 83-87.	4.5	8
98	Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma. <i>Molecular Cytogenetics</i> , 2015, 8, 78.	0.9	8
99	Colonic epithelial cathelicidin (<sc>LL</sc>â€³7) expression intensity is associated with progression of colorectal cancer and presence of <sc>CD8</sc>⁺ T cell infiltrate. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 495-506.	3.0	8
100	Combined linkage and association analysis of classical Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 20377-20385.	1.8	8
101	Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?. <i>Digestive Surgery</i> , 2019, 36, 495-501.	1.2	7
102	Screen detection is a survival predictor independent of pathological grade in colorectal cancer. A prospective cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021, 19, 20-26.	1.8	7
103	Cytochrome P450 1B1 expression in human malignant tumours. <i>Biochemical Society Transactions</i> , 1996, 24, 328S-328S.	3.4	6
104	Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating $\hat{\pm}4\hat{2}7$ Integrin CD4+ T Cells: Implications for HIV Microbicides. <i>Molecular Pharmaceutics</i> , 2016, 13, 3334-3340.	4.6	6
105	Interleukin-27 Regulates the Function of the Gastrointestinal Epithelial Barrier in a Human Tissue-Derived Organoid Model. <i>Biology</i> , 2022, 11, 427.	2.8	5
106	Letters to the editor. <i>Journal of Pathology</i> , 1995, 176, 319-324.	4.5	4
107	Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. <i>Colorectal Disease</i> , 2021, 23, 1326-1333.	1.4	4
108	Matrix metalloproteinaseâ€¹ is associated with poor prognosis in oesophageal cancer. <i>Journal of Pathology</i> , 1998, 185, 256-261.	4.5	4

#	ARTICLE	IF	CITATIONS
109	Gut Mucosal Microbiome Signatures of Colorectal Cancer Differ According to BMI Status. <i>Frontiers in Medicine</i> , 2021, 8, 800566.	2.6	4
110	Following the protein biomarker trail to colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 93-96.	0.8	3
111	Pharmacogenomics of Cytochrome P450 Enzymes in Tumours. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2004, 2, 243-254.	0.3	3
112	Laser Capture Microdissection: Applications in Urological Cancer Research. <i>UroOncology</i> , 2002, 2, 33-35.	0.1	3
113	Expression of matrix metalloproteinases in colorectal cancer. <i>Biochemical Society Transactions</i> , 1996, 24, 329S-329S.	3.4	2
114	Proteomics of Bone and Soft Tissue Sarcomas. <i>Current Proteomics</i> , 2012, 9, 94-102.	0.3	2
115	Has the proteome of formalin-fixed wax-embedded tissue been unlocked?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3395-3398.	0.7	2
116	Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 361-377.	2.3	2
117	The role of cytochrome P450 in tumour development and progression and its potential in therapy. <i>Journal of Pathology</i> , 2000, 192, 419-426.	4.5	2
118	Matrix metalloproteinases in tumour invasion and metastasis. , 0, .		1
119	Identification of a prognostic signature in colorectal cancer using combinatorial algorithm-driven analysis. <i>Journal of Pathology: Clinical Research</i> , 2022, , .	3.0	1
120	Semi-thin? semi-thick?. <i>Journal of Pathology</i> , 1989, 158, 267-267.	4.5	0
121	Expression of a DNA binding protein in tumours. <i>Biochemical Society Transactions</i> , 1996, 24, 252S-252S.	3.4	0
122	66 Theta-class glutathione S-transferases in human kidney and renal tumours. <i>Biochemical Society Transactions</i> , 1997, 25, S605-S605.	3.4	0
123	PWE-010...Defining interleukin-27 effects on the epithelial barrier " a new therapeutic for IBD?. , 2018, , .		0
124	PTU-056...Loss of cathelicidin (LL-37) is associated with colorectal cancer progression. , 2018, , .		0
125	PTU-040...HMGB1 in the pathogenesis of colorectal cancer. , 2018, , .		0
126	Proteomics in Urological Cancer Research. <i>UroOncology</i> , 2002, 2, 163-166.	0.1	0